Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

GE Launches Heart-Muscle Tox Test

October 6, 2010 7:19 am | News | Comments

Geron says GE Healthcare is now selling a human cardiomyocyte-based toxicology screening product the companies developed together.

TOPICS:

Three Win Nobel Prize Key Chemical Tool

October 6, 2010 7:13 am | by Karl Ritter | News | Comments

An American and two Japanese scientists won the Nobel Prize in chemistry for finding new ways to bond carbon atoms together, methods now widely used to make medicines and even slimmed-down computer screens.

TOPICS:

FDA Warns Gilead on Manufacturing Issues

October 6, 2010 7:09 am | by Matthew Perrone | News | Comments

The Food and Drug Administration posted a warning letter on its website, outlining more than a half-dozen quality-control problems uncovered by inspectors on a routine visit to Gilead's San Dimas, Calif., facility.

TOPICS:
Advertisement

Novartis Cancelling Two Drugs

October 6, 2010 7:06 am | News | Comments

Novartis AG said it will take a charge of $590 million during the third quarter as it discontinues development of a potential hepatitis C drug and an antifungal product.

TOPICS:

Judge Approves $600M Botox Settlement

October 6, 2010 6:58 am | by Greg Bluestein | News | Comments

A federal investigation into Allergan Inc.'s misleading marketing of its wrinkle-smoothing Botox medication is over after a judge in Georgia approved the pharmaceutical firm's decision to pay $600 million and plead guilty to misbranding the product.

TOPICS:

Pfizer May Sell Capsugel

October 6, 2010 6:54 am | News | Comments

Pfizer Inc. said it is reviewing its strategic alternatives for its Capsugel business unit, which makes hard capsules used to deliver medication.

TOPICS:

J & J Acquiring Crucell for $2.4B

October 6, 2010 6:52 am | News | Comments

Johnson & Johnson said it is buying Crucell N.V. for about $2.41 billion in a move that will boost the American health care company's vaccine business.

TOPICS:

Culture Surface

October 5, 2010 8:43 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced the Nunclon Vita stem cell culture surface. The energy-treated polystyrene surface enables direct attachment, colony formation, and growth of human embryonic stem cells and induced pluripotent stem cells.

TOPICS:
Advertisement

Human Cardiomyocytes

October 5, 2010 8:29 am | Product Releases | Comments

GE Healthcare announces the availability of human cardiomyocytes that provide a more readily available and biologically-relevant alternative to current cell models and primary cells used in drug discovery and predictive toxicity testing.

TOPICS:

Biocontainers

October 5, 2010 8:25 am | Product Releases | Comments

TepoFlex biocontainers provide secure, robust fluid handling options. TepoFlex polyethylene-based biocontainers are available in 2D end-ported designs from 250 mL to 20 L and 2D face-ported designs from 5 L-200 L.

TOPICS:

Isogenica Collaborating With NovaBiotics

October 5, 2010 8:12 am | News | Comments

Isogenica Ltd, announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of Novabiotic’s anti-infective peptide technology platform.

TOPICS:

Evotec In Deal With Shionogi

October 5, 2010 8:08 am | News | Comments

Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. to identify small molecule modulators of various protein-protein interaction targets.

TOPICS:

Onconova And FDA Agree on Phase 3 Trial Design

October 5, 2010 8:05 am | News | Comments

Onconova Therapeutics, Inc. announced agreement with the FDA regarding an SPA for the design of a pivotal Phase 3 trial for Estybon as monotherapy in patients with myelodysplastic syndromes, diseases affecting the production of healthy blood cells.

TOPICS:

PROLOR Receives Orphan Drug Designation

October 5, 2010 7:55 am | News | Comments

PROLOR Biotech, Inc. announced that the FDA has granted orphan drug designation to hGH-CTP, PROLOR’s longer-acting version of human growth hormone for the treatment of growth hormone deficiency. hGH-CTP is currently in a Phase 2 clinical trial.

TOPICS:

X-Rays Linked to Childhood Leukemia

October 5, 2010 7:40 am | News | Comments

Researchers have discovered that children with acute lymphoid leukemia had almost twice the chance of having been exposed to three or more X-rays compared with children who did not have leukemia.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading